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ABSTRACT
Background. Fosfomycin, effective in Cystic Fibrosis (CF), competes with aminoglycosides at renal binding sites and may
therefore afford a renoprotective effect when used in combination therapy. We explored this by using markers of acute
renal tubular damage [N-acetyl-b-D-glucose-aminidase (NAG), alanine amino-peptidase (AAP) and b2-microglobulin].
Methods. Using a prospective randomized crossover trial design, at an acute pulmonary exacerbation, 18 adult CF patients
received either 14 days of intravenous (IV) tobramycin or IV tobramycin and IV fosfomycin, both in combination with a
second IV antibiotic (colomycin).
Results. Urinary NAG (P¼0.003) and AAP (P¼0.03) following treatment with concomitant fosfomycin were lower than those
after treatment with tobramycin and colomycin alone. Fosfomycin attenuated the total 24-h urinary protein leak
(P¼0.0001). The 14-day improvements in all surrogate markers of exacerbation resolution (FEV1% predicted, FVC, white cell
count and C-reactive protein) were similar for both treatment regimens.
Conclusions. The addition of fosfomycin reduces acute renal injury caused by IV aminoglycoside therapy in CF pulmonary
exacerbations.
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INTRODUCTION
Effective antibiotic therapy is critical in CF, where pulmonary
exacerbations typically caused by bacteria such as Pseudomonas
aeruginosa (Psa) are associated with clinical decline and in-
creased morbidity.
Multiresistant isolates of Psa are an increasing problem. The
most effective treatment regimen in CF pulmonary Psa exacer-
bations is still uncertain. It is recommended that respiratory
exacerbations are treated with two intravenous (IV) antibiotics
to minimize the risk of antibiotic resistance developing [1, 2].
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Combined therapy may have an additive or synergistic effect.
The initial choice of antibiotic still depends on in vitro bacterial
sensitivity patterns and often includes an aminoglycoside.
Although aminoglycosides are powerful anti-pseudomonal
agents and their use in CF is widespread and unavoidable, they
are resorbed by the proximal renal tubule and have the poten-
tial for nephrotoxicity. Indeed, acute renal injury is common
and we have previously shown a link between repeated IV ami-
noglycoside use in CF patients and cumulative nephrotoxicity
[3]. The continuing use of IV aminoglycosides in CF necessitates
the development of strategies to reduce their negative renal
impact.
Fosfomycin (1, 2-epoxy-propyl-phosphonic acid), originally
isolated from Streptomyces fradiae [4], is now produced syntheti-
cally. It competes for the same renal binding sites as aminogly-
cosides. Animal models suggest that it might attenuate the
nephro- [5, 6] and oto- [7] toxicity of aminoglycosides when co-
administered. Furthermore, it has useful activity against Psa [8]
and good lung tissue and biofilm penetration following IV ad-
ministration [9].
We have previously demonstrated the efficacy of fosfomycin
in CF pulmonary Psa exacerbations [10]. However, its potential
renoprotective properties have not been evaluated in CF and to
investigate this further, we conducted a prospective
randomized crossover study of its use in combination with
tobramycin and a second antibiotic (colomycin) in the treat-
ment of Psa exacerbations.
MATERIALS ANDMETHODS
Study population
People with CF chronically infected with Psa experiencing two
or more pulmonary exacerbations in the preceding 12 months
and requiring admission to hospital formed the study popula-
tion. Chronic Psa infection was defined as three or more posi-
tive sputum cultures within the previous 12 months [11]. An
exacerbation was defined as the need for additional antibiotic
treatment as indicated by a recent change in sputum volume or
colour; increased cough; increased malaise, fatigue or lethargy;
anorexia or weight loss; or radiographic changes or increased
dyspnoea [12] associated with a decrease in FEV1% from stable
outpatient clinic baseline. Those with known intolerance to
aminoglycosides, colomycin or fosfomycin had Psa isolates re-
sistant to tobramycin or colomycin, a history of Burkholderia
cepacia (B. cepacia) isolation in the preceding 12 months, signifi-
cant haemoptysis or new radiographic changes, had received
any aminoglycoside (IV or nebulized) therapy during the previ-
ous 3 months or any additional anti-pseudomonal antibiotic in
the 2 weeks prior to admission, or did not experience a second
exacerbation within 1 year were excluded (Figure 1). All
refrained from vigorous physical exercise for 2 days prior to the
study. Eighteen CF patients [mean (SD) age 21.8 (3.4) years, FEV1
59.3 (15.1) % predicted, body mass index (BMI) 21.2 (2.4) kg/m2,
10 males] completed the study.
Four had CFRD at enrolment and no new cases of diabetes
were diagnosed in the remainder over the study period.
Written informed consent was obtained, and the study was
approved by the local research ethics committee at the
Liverpool Heart and Chest Hospital, UK.
Study design
At the first exacerbation, patients were randomized to receive
14 days of either IV tobramycin/colomycin (in line with the stan-
dard practice of using a minimum of two anti-pseudomonal
antibiotics to treat pulmonary exacerbations in CF) or IV tobra-
mycin/colomycin/fosfomycin. At the second exacerbation,
patients received the alternative antibiotic combination.
IV tobramycin (80 mg/2 mL, Mayne Pharma Plc, UK) was
given in two to three divided doses to achieve a trough level of
<2.0 mg/L and a peak level of 6–10 mg/L (in keeping with recom-
mended protocols). Levels were subsequently measured as
needed to ensure therapeutic serum concentrations [mean (SD)
daily dose of 7.6 (SD 0.8) mg/kg in the tobramycin/colomycin
arm and 7.9 (0.9) mg/kg in the tobramycin/colomycin/fosfomycin
arm; P¼ 0.82]. IV colistimethate sodium (ColomycinVR injection,
Forest Laboratories Ltd, UK) was given at a fixed dose of 2 MU
three times a day (tid), and IV fosfomycin disodium (5 g powder
for reconstitution, Idis Pharma, UK) at a fixed dose of 5 g tid.
Outcomemeasures
The primary efficacy endpoint was the antibiotic-related
change from baseline to Day 14 in urinary levels of the proximal
tubular enzymes N-acetyl-b-D-glucose-aminidase (NAG), ala-
nine amino-peptidase (AAP) and the tubular protein b2-micro-
globulin (b2M). Renal indices also included serum creatinine
(SCr) and magnesium (Mg2þ) assays, 24-h urine collection for
FIGURE 1: Flow diagram of study selection.
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measurement of creatinine clearance (CCl) and total protein-
uria/albuminuria.
Secondary efficacy endpoints were changes in spirometry
(FEV1, FVC), peripheral blood white cell count, C-reactive protein
levels and the time to next exacerbation. Safety endpoints in-
cluded adverse events (AEs) and toxic serum tobramycin
concentrations.
Laboratory methods
Sputa at the beginning and end of the treatment were collected
and processed using standard microbiological methods. Serum
tobramycin concentrations were measured using TDxFLx assay
(Abbott Laboratories). Serum and urine creatinine were mea-
sured by the Jaffe reaction and CCl calculated as urine volume 
urine creatinine/SCr (expressed as mL/min).
NAG was measured using a commercial assay kit (PPR
Diagnostics, London, UK) and the effects of varied urine concen-
tration minimized by expressing NAG levels as a ratio of urine
creatinine (i.e. units/mmol creatinine).
AAP (units/mmol creatinine) was measured using a modifi-
cation of a procedure described by Jung and Scholz [13] with the
change in absorbance at 410 nm calibrated by reference to a
standard curve of known concentration of p-nitroaniline
product.
After buffering to a pH of 7.0, b2M (lg/mmol creatinine) was
measured using a solid immune-radiometric assay (Euro/DPC,
Llanberis, UK).
Urine total protein and albumin were quantified by a turbidi-
metric method in a Roche Clinical Chemistry analyser (Wako,
Japan).
Statistical analysis
Based on published mean (SD) improvements in FEV1 after IV
antibiotic therapy of CF pulmonary exacerbations and our cen-
tre data of antibiotic-related changes in renal function, 130
patients would have been required to adequately power a study
to detect a superior or non-inferior effect from the addition of
fosfomycin comparing different antibiotic regimens. This num-
ber would have been more appropriate for a multicentre trial,
which was not feasible; hence, we undertook a pragmatic
single-centre pilot study, based on the resources available.
Baseline demographics were compared using a paired t-test
or Chi-squared test. Pulmonary function, blood, sputum and
urine test results on Days 0 and 14 are presented graphically as
median and IQR. Within-group Days 0–14 changes were
assessed using a paired t-test (parametric data) or the Wilcoxon
signed rank test (non-parametric data). Treatment effects are
presented as the mean [95% confidence interval (CI)] or median
(IQR) difference between treatment-induced changes and ana-
lysed using a paired t-test or Wilcoxon signed rank test as ap-
propriate. D’Agostino and Pearson’s normality tests were used
to assess data distribution throughout. Comparison of time to
next exacerbation was conducted with Kaplan–Meier survival
curves and a log-rank test. Results are presented as means (SD)
unless otherwise stated.
RESULTS
All 18 patients completed both arms of the study (i.e. 36 treat-
ment episodes). Table 1 shows baseline parameters at the start
of each treatment. The mean (SD) interval between admissions
was 4.6 months (2.9; range 1–11). Allowing for age change and
baseline patient characteristics, the remainder of their therapy
was otherwise identical in the two inpatient episodes.
Changes in renal function
Urinary levels of the proximal tubular enzymes NAG and AAP
after 14 days treatment with tobramycin/colomycin/fosfomycin
were significantly lower than those recorded after treatment
with tobramycin/colomycin alone. There were lower b2M levels
on triple therapy (Table 2 and Figure 2) although the difference
did not reach statistical significance. The addition of fosfomycin
to tobramycin/colomycin also attenuated the antibiotic-
induced total urinary protein leak in a 24-h collection
(P< 0.0001), but urinary albumin did not alter from baseline and
did not differ between the two treatments.
Except for comparable improvements in CCl, none of the
other renal indices changed significantly with either treatment.
There were no instances of AKI by the KDIGO definition in ei-
ther arm of the study.
Recovery from exacerbation
The mean 14-day improvements in all surrogate markers of ex-
acerbation resolution were not statistically different between
both treatments (Table 3).
Time to next exacerbation
The addition of fosfomycin did not impact on the time to next
exacerbation requiring hospitalization. The interval between
two consecutive hospital admissions was 4.2 (2.9) and 5.0 (1.3)
months for patients treated initially with tobramycin/colomycin
and tobramycin/colomycin/fosfomycin, respectively (v2 test ¼
0.89; HR ¼ 1.52, 95% CI 0.59–4.41; P¼ 0.35).
Sputummicrobiology
Thirty-one (86%) sputa were collected prior to treatment: all
harboured Psa susceptible to tobramycin and colistin in vitro on
standard disc diffusion testing. Psa eradication was not
Table 1. Baseline characteristics of lung function (FEV1%, FVC), BMI,
renal indices and renal markers at the start of each treatment
TOBþ COL
(n¼ 18)
TOBþCOLþ
FOM (n¼ 18)
FEV1 % (predicted) 48.3 (13.1) 47.2 (13.8)
FVC % (predicted) 67.9 (10.0) 65.4 (8.1)
BMI (kg/m2) 21.9 (2.6) 21.6 (2.7)
Blood urea (mmol/L) 4.4 (0.9) 4.2 (0.8)
SCr (lmol/L) 81.6 (10.1) 82.0 (11.8)
Serum Mg2þ (mmol/L) 0.90 (0.15) 0.83 (0.17)
CCl (mL/min) 84.3 (21.2) 81.4 (19.7)
24-h urine protein excretion (g) 0.08 (0.05) 0.07 (0.05)
Urinary albumin (mg/mmol) 1.6 (0.7) 1.8 (0.6)
Urinary NAG (IU/mmol) 0.28 (0.12–0.45) 0.26 (0.10–0.61)
Urinary AAP (IU/mmol) 0.95 (0.52) 0.84 (0.54)
Urinary b2M (lg/mmol) 20.76 (11.90–30.25) 18.58 (12.00–28.50)
TOB daily dose (mg/kg) 7.6 (0.8) 7.9 (0.9)
COL daily dose (MU) 6 (–) 6 (–)
FOM daily dose (g) N/A 15 (–)
Data are presented as mean (SD) or median (IQR) as appropriate.
COL, colomycin (colistimethate sodium); FOM, fosfomycin disodium; TOB, tobra-
mycin; N/A, not applicable.
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Table 2. Renal and urinary markers for each treatment group
Test TOBþCOL TOBþCOLþ FOM
Difference between treatments
(95% CI for difference) P-value
Urea 0.68 (1.64) 0.62 (1.59) 0.06 (1.154 to 1.034) 0.91
Creatinine 4.33 (10.22) 2.17 (9.78) 2.16 (8.936 to 4.616) 0.52
CCl 17.28 (17.13) 19.89 (14.64) 2.61 (8.128 to 13.348) 0.64
Mg2þ 0.05 (0.02) 0.05 (0.19) 0.1 (0.032 to 0.232) 0.13
Total proteinuria 0.27 (0.20) 0.04 (0.07) 0.23 (0.331 to 0.129) 0.0001
Albuminuria 0.19 (0.47) 0.25 (0.60) 0.06 (0.313 to 0.417) 0.77
NAG 1.38 (0.63–4.38) 0.53 (0.24–1.36) 1.24 (3.313 to 0.447) 0.0028
AAP 30.1 (33.4) 11.8 (11.04) 18.3 (35.15 to 1.45) 0.03
b2M 111.9 (19.0–179.80) 14.3 (0.16–118.8) 57.50 (0.1806 to 0.0126) 0.1297
Data are presented as mean (SD) or median (IQR) as appropriate. Unadjusted P-values are presented throughout. Change in renal indices and renal markers from the
start of each treatment to Day 14 and comparison between treatments tobramycin/colomycin and tobramycin/colomycin/fosfomycin.
COL, colomycin (colistimethate sodium); FOM, fosfomycin disodium; TOB, tobramycin.
FIGURE 2: Change in renal markers from the start of (Day 0) to end (Day 14) of each treatment and comparison between treatments tobramycin/colomycin (TOB þ COL)
and tobramycin/colomycin/fosfomycin (TOB þ COL þ FOM).
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observed and treatment-emergent super-infection with new CF
pathogens such as Burkholderia species, Stenotrophomonas mal-
tophilia or other resistant Gram-negative bacteria was not
recorded in any treatment episode.
Safety
AEs. There were no AEs warranting withdrawal of therapy. The
incidence of AEs was comparable during both treatments
(Table 4).
Serum tobramycin levels. Serum tobramycin assays were not
statistically different throughout both treatments, and no toxic
drug levels were recorded in either treatment arm.
DISCUSSION
Improving survival in CF has brought new complications as a
consequence of a lifetime of necessarily aggressive treatment
regimens. Renal disease in people with CF is becoming increas-
ingly recognized as they accumulate exposure to nephrotoxic
therapy, including aminoglycosides, which are a mainstay of
treatment for Psa. Alternative strategies that spare aminoglyco-
side renal side-effects are necessary. For the first time, we have
shown that fosfomycin may be useful in reducing the acute re-
nal injury caused by aminoglycosides.
SCr on its own is a poor marker of renal function in CF. Due
to their nutritional challenges, poor muscle mass and recurrent
infections, many CF patients do not have normal or stable SCr
levels, further complicating the use of readily available surro-
gate markers of renal function such as measured or estimated
CCl [14]. Hence, more accurate indices of renal disease are nec-
essary in CF. Since the primary nephrotoxic effect of aminogly-
cosides is on the proximal tubular epithelium [15], the release of
cell-bound enzymes can then serve as sensitive markers of
acute renal injury before conventional laboratory assays be-
come deranged [14], and we therefore used these in our study.
Indeed, these urine biomarkers have already been employed to
study nephrotoxicity caused by immunosuppressive drugs [16]
and antibiotics [17]. We used NAG, AAP and b2M for this pur-
pose, where elevated urinary levels indicate the site of primary
tubular cell damage (AAP: brush border, NAG: tubular lyso-
somes) [18].
NAG is present in high concentrations in the proximal tubu-
lar cells, and its molecular weight (140 kDa) does not permit
glomerular filtration. Raised urinary levels reflect proximal re-
nal tubular dysfunction, and elevated urinary NAG excretion
during IV aminoglycoside use in people with CF is well de-
scribed [14, 19].
Elevated urinary AAP precedes increase in SCr in patients
with renal toxicity [14]. The assay [13] can detect differences in
enzymuria between various treatment regimens [17] and differ-
ent severity groups of non-drug-related renal disease [20]. We
chose AAP as a marker in this study because of its specificity to
the proximal tubule cell, and changes in urinary AAP should
therefore mirror those in NAG.
b2M, a low molecular weight (12 kDa) plasma protein, is nor-
mally filtered at the glomerulus and completely reabsorbed by
the proximal tubules where it is catabolized. Increased urinary
b2M leak has been found to correlate with altered renal function
secondary to aminoglycoside exposure [21].
Other markers including neutrophil gelatinase-associated
lipocalin (NGAL) and kidney injury molecule 1 are thought to be
better associated with acute kidney insult [22, 23]. However,
NGAL is also produced in response to damaged epithelial cells
in the lung [24], confounding its utility in the CF condition.
Another marker tissue inhibitor of metalloproteinase 2 (TIMP-
2)IGFBP7, which is a combination of urine TIMP-2 and insulin-
like growth factor (IGF) binding protein 7 (IGFBP7), has been
identified as a potential biomarker of AKI. Its urinary levels rise
early after first antibiotic administration. However, given the
significant heterogeneity among studies [25], caution has to be
exercised about the utility and limitations of this biomarker in
clinical practice, especially as there are no prior clinical studies
validating its application in CF. Hence, we did not include these
markers in our study.
In our study, although significant differences between the
two regimens were shown with NAG and AAP, the impact of
fosfomycin on b2M levels was less dramatic.
Table 3. Surrogate markers of exacerbation resolution
Test TOB þ COL TOB þ COL þ FOM
Mean difference between treatments
(95% CI for difference) P-value
FEV1% (predicted) þ12.6 (8.0) þ11.8 (5.9) 0.8 (5.6 to 4.0) 0.73
FVC% (predicted) þ14.1 (7.7) þ15.9 (6.9) 1.8 (3.15 to 6.75) 0.46
WCC 2.9 (6.3) 3.3 (4.1) 0.4 (4.0 to 3.2) 0.82
CRP 27 (26.8) 34 (30.0) 7 (26.3 to 12.3) 0.47
Data are presented as mean (SD). Change in lung function and inflammatory markers from the start of each treatment to Day 14 and comparison between treatments
tobramycin/colomycin and tobramycin/colomycin/fosfomycin.
COL, colomycin (colistimethate sodium); CRP, C-reactive protein; FOM, fosfomycin disodium; TOB, tobramycin; WCC, white cell count.
Table 4. Number (%) of patients reporting treatment emergent AE
AE TOBþCOL TOB þ COL þ FOM
Aggravated cough 3 (17) 3 (17)
Increased sputum 3 (17) 4 (22)
Acute bronchospasm/chest
tightness
2 (11) 0 (0)
Sore throat/hoarseness 2 (11) 2 (11)
Reduced hearing 2 (11) 1 (11)
Tinnitus 2 (11) 0 (0)
Dizziness 3 (17) 1 (17)
Paraesthesia 1 (6) 1 (6)
Nausea 2 (11) 3 (17)
Diarrhoea 2 (11) 3 (17)
Treatment episodes with any
reported AE
8 (44) 9 (50)
COL, colomycin; FOM, fosfomycin; TOB, tobramycin.
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There are several possible explanations for this. First, al-
though NAG and AAP reflect tubular structural integrity, b2M
only acts as a surrogate marker of functional competency of the
proximal tubular epithelium [26], but has traditionally been
used in clinical practice to detect renal tubular damage [27]. It
may well be that, unlike shorter drug challenges in animal stud-
ies [5, 6], continued exposure to tobramycin may have caused a
functional change despite the relative structural preservation
afforded in the fosfomycin arm. Secondly, b2M degrades very
rapidly at 37C in the acidic (pH< 5.5) environment of the uri-
nary bladder [28], and despite adjusting all samples to pH¼ 7
immediately after collection, it is possible that some degrada-
tion may have occurred thus confounding the urinary yield of
b2M and diluting any true protective effect with fosfomycin.
Nevertheless, there were lower urinary b2M levels in the fos-
fomycin arm, and this is in keeping with the significantly lower
total protein leak that was also noted. Since urine albumin lev-
els were not different in both arms, this could not have been
simply due to glomerular-related proteinuria.
Using these assays, we have demonstrated that incorporat-
ing fosfomycin into the antibiotic treatment of CF pulmonary
exacerbations offers some protection against the immediate
proximal tubular injury caused by tobramycin. Previously only
described in animal models [5, 6], this is the first report to repro-
duce the nephroprotective properties of fosfomycin against
aminoglycoside-induced tubulotoxicity in people with CF.
Furthermore, a number of studies have shown the utility of
fosfomycin as an anti-Psa antibiotic in people with CF [10, 29,
30]. It is actively taken up by bacterial cells through two nutrient
transport systems and inhibits the initial step in cell wall syn-
thesis [31] present in various bacteria (including Psa). However,
in vitro susceptibility testing for fosfomycin against Psa requires
the presence of glucose-6-phosphate, which is not routinely in-
corporated into standard sensitivity testing agars such that sen-
sitive strains may appear resistant [32], and indeed 28/36 Psa
isolates in our cohort were reported to be fosfomycin-resistant.
Co-administration of fosfomycin may also enhance other
antibiotics for a number of reasons. First, it can penetrate the
negatively charged polysaccharide biofilm in the CF lung, which
protects organisms from specific antibodies and other antibiotics.
Secondly, a synergistic in vitro effect has been demonstrated in
combination with ofloxacin against Psa growing in biofilm [33] and
with ciprofloxacin against CF Psa isolates [34]. Thirdly, because it
acts on different synthetic pathways, it reduces the potential for
the development of cross resistance with other classes of antibiot-
ics [35, 36]. Finally, it has excellent tolerability: there are no reports
in the literature of the side effects of the IV formulation. Its poten-
tial to ameliorate aminoglycoside-associated nephrotoxicity in this
study adds further support to its utility in the CF population.
In conclusion, people with CF chronically infected with Psa
require repeated courses of IV anti-pseudomonal antibiotics
and the frequent use of a limited selection of antibiotics encour-
ages the development of resistance and increased toxicity in-
cluding cumulative renal impairment. Fosfomycin is a unique
bactericidal antibiotic, which expands the range of anti-
pseudomonal therapy available for CF patients, and is safe and
well tolerated with valuable renal-sparing properties. Whether
this translates into clinically meaningful preservation of renal
function needs to be ascertained in larger long-term studies.
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